Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1971 2
1977 1
1990 1
1992 1
1997 1
1998 2
1999 5
2000 5
2001 4
2002 2
2003 5
2004 5
2005 5
2006 10
2007 3
2008 3
2009 9
2010 12
2011 4
2012 5
2013 6
2014 5
2015 6
2016 7
2017 14
2018 13
2019 21
2020 13
2021 11
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

152 results
Results by year
Filters applied: . Clear all
Page 1
Effects of caffeine on sleep quality and daytime functioning.
O'Callaghan F, Muurlink O, Reid N. O'Callaghan F, et al. Risk Manag Healthc Policy. 2018 Dec 7;11:263-271. doi: 10.2147/RMHP.S156404. eCollection 2018. Risk Manag Healthc Policy. 2018. PMID: 30573997 Free PMC article. Review.
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial.
Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA, O'Callaghan FJ, Wong M, Sahebkar F, Checketts D, Knappertz V; GWPCARE6 Study Group. Thiele EA, et al. Among authors: o callaghan fj. JAMA Neurol. 2021 Mar 1;78(3):285-292. doi: 10.1001/jamaneurol.2020.4607. JAMA Neurol. 2021. PMID: 33346789 Free PMC article. Clinical Trial.
O'Callaghan F. O'Callaghan F. Dev Med Child Neurol. 2021 Jan;63 Suppl 1:3. doi: 10.1111/dmcn.14771. Dev Med Child Neurol. 2021. PMID: 33378088 Free article. No abstract available.
Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations.
Curatolo P, Nabbout R, Lagae L, Aronica E, Ferreira JC, Feucht M, Hertzberg C, Jansen AC, Jansen F, Kotulska K, Moavero R, O'Callaghan F, Papavasiliou A, Tzadok M, Jóźwiak S. Curatolo P, et al. Among authors: o callaghan f. Eur J Paediatr Neurol. 2018 Sep;22(5):738-748. doi: 10.1016/j.ejpn.2018.05.006. Epub 2018 May 24. Eur J Paediatr Neurol. 2018. PMID: 29880258 Review.
Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial.
O'Callaghan FJ, Edwards SW, Alber FD, Hancock E, Johnson AL, Kennedy CR, Likeman M, Lux AL, Mackay M, Mallick AA, Newton RW, Nolan M, Pressler R, Rating D, Schmitt B, Verity CM, Osborne JP; participating investigators. O'Callaghan FJ, et al. Lancet Neurol. 2017 Jan;16(1):33-42. doi: 10.1016/S1474-4422(16)30294-0. Epub 2016 Nov 10. Lancet Neurol. 2017. PMID: 27838190 Free article. Clinical Trial.
The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.
Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O'Callaghan FJ, Verity CM, Osborne JP; United Kingdom Infantile Spasms Study. Lux AL, et al. Among authors: o callaghan fj. Lancet Neurol. 2005 Nov;4(11):712-7. doi: 10.1016/S1474-4422(05)70199-X. Lancet Neurol. 2005. PMID: 16239177 Clinical Trial.
Tuberous sclerosis.
O'Callaghan FJ. O'Callaghan FJ. BMJ. 1999 Apr 17;318(7190):1019-20. doi: 10.1136/bmj.318.7190.1019. BMJ. 1999. PMID: 10205080 Free PMC article. No abstract available.
Prophylactic Antiepileptic Treatment in Tuberous Sclerosis.
Choudhury P, Spaull R, Amin S, Mallick AA, Patel JS, O'Callaghan F, Lux AL. Choudhury P, et al. Among authors: o callaghan f. Pediatr Neurol. 2020 Sep;110:100-101. doi: 10.1016/j.pediatrneurol.2020.03.017. Epub 2020 Apr 5. Pediatr Neurol. 2020. PMID: 32414624 No abstract available.
152 results